Margetuximab Plus Chemo Improves PFS in HER2-Positive, Metastatic Breast Cancer
Hope S. Rugo, MD, University of California San Francisco Comprehensive Cancer Center, discusses the clinical significance of the phase 3 SOPHIA clinical trial, the findings of which were presented at the 2019 ASCO Annual Meeting.
Margetuximab Plus Chemo Improves PFS in HER2-Positive, Metastatic Breast Cancer from HMP on Vimeo.
